SEARCH:   Advanced

Blood, Vol. 108, Issue 13, 4194-4197, December 15, 2006 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef CD200 is a new prognostic factor in multiple myeloma Blood Moreaux et al. 108: 4194 Supplemental materials for: Moreaux et al, Vol 108, Issue 13, 4194-4197 Files in this Data Supplement: Table S1. Clinical data of patients with CD200present and CD200absent myeloma cells (JPG, 124 KB) - One hundred and twelve newly diagnosed patients with MM were separated into 2 groups: patients with MMC expressing CD200 (CD200present) and patients with MMC lacking CD200 expression (CD200absent), as assayed with Affymetrix microarrays. The data are the percentages of patients within the 2 groups with the indicated clinical or biologic parameters. When the percentages were different with the chi-square test (P ≤ .05), data are shown in bold and italic. NS indicates not significant. Figure S1. Validation of Affymetrix data with real-time RT-PCR analysis (JPG, 68.4 KB) - Gene expressions of C200 in 20 HMCLs and 5 patients’ MMCs were assayed with real-time RT-PCR and normalized with GAPDH expression. The coefficient of correlation between Affymetrix and real-time RT-PCR values was determined. Figure S2. Validation of Affymetrix data with cytometry analysis (JPG, 50.3 KB) - CD200 expression of 20 HMCLs was determined using labeling of MMCs with a PE-conjugated anti-CD200 MoAb or a PE-conjugated isotype-matched control antibody. The coefficient of correlation between Affymetrix and protein expression was determined. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020